Latest / Breaking News To Trading Moves
Vanda Pharmaceuticals: The Tradipitant FDA Approval Catalyst
Vanda Pharmaceuticals (VNDA) jumps after FDA approves its motion-sickness drug Nereus (tradipitant)
What happened
On December 30–31, 2025, the FDA approved Vanda’s Nereus (tradipitant) to prevent vomiting induced by motion. It’s the first new FDA-approved treatment for motion-induced vomiting in over 40 years, and Vanda says it plans to launch in the coming months.
Why the market cares
1. A brand-new FDA label creates a near-term commercial story (launch, pricing, payer coverage, distribution).
2. It also validates tradipitant as a platform asset, with Vanda pursuing other nausea/vomiting…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.